Bone mineral content in nephrotic children on long-term, alternate-day prednisone therapy

Area of Science:

• Pediatric Nephrology
• Endocrinology
• Bone Metabolism

Background:

• Steroid-dependent minimal-lesion nephrotic syndrome (MLNS) is a common childhood kidney disease.
• Long-term corticosteroid use, including prednisone, raises concerns about potential adverse effects on bone health.
• Alternate-day prednisone therapy is a common regimen to minimize side effects in pediatric MLNS.

Purpose of the Study:

• To evaluate the effect of alternate-day prednisone therapy on bone mineral content (BMC) in children with steroid-dependent MLNS.
• To determine if the duration or dosage of prednisone correlates with changes in BMC.
• To compare BMC in treated children with a healthy, age- and sex-matched control group.

Main Methods:

• Bone mineral content (BMC) was measured using single-photon absorptiometry.
• The study included 24 children with steroid-dependent MLNS undergoing alternate-day prednisone therapy.
• A control group of sex- and age-matched healthy children was included for comparison.

Main Results:

• No significant difference in BMC was observed between children with MLNS and the control group (P = 0.25).
• BMC standard deviation scores were -0.002 +/- 1.2 in patients and 0.3 +/- 1.4 in controls.
• No significant correlation was found between BMC and prednisone dosage or therapy duration.

Conclusions:

• Alternate-day prednisone therapy, at typical doses for managing steroid-dependent nephrotic syndrome, does not significantly affect bone mineral content in children.
• Current therapeutic strategies using alternate-day prednisone appear to preserve bone health in pediatric patients with MLNS.
• Further long-term studies may be warranted to confirm these findings across diverse patient populations.